# An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

> **NCT04443088** · PHASE1 · RECRUITING · sponsor: **Shenzhen Ionova Life Sciences Co., Ltd.** · enrollment: 78 (estimated)

## Conditions studied

- Cancer
- Solid Tumor, Adult
- Cancer Metastatic
- Solid Carcinoma
- Solid Tumor, Unspecified, Adult
- Tumor, Solid

## Interventions

- **DRUG:** INV-1120
- **COMBINATION_PRODUCT:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04443088
- **Lead sponsor:** Shenzhen Ionova Life Sciences Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-06-26
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2026-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04443088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04443088, "An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT04443088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*